RxDoctor Payments Data

Gary Miller, MD

Psychiatry · Houston, TXNPI 1770503336

Payments from drug & device makers

$2,947in general payments, 2019–2025

Across 244 payments — averaging $12.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$703
  • Teva Pharmaceuticals USA, Inc.$398
  • Supernus Pharmaceuticals, Inc.$337
  • AbbVie$182
  • Johnson & Johnson$170
  • Vanda Pharmaceuticals Inc.$165
  • plus $991 from 14 others

What the payments were for

  • Food & beverage$2,90098%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,947 in reported general payments places this provider in the 80th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$22,367
Medicare patients
122
Services billed
216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aripiprazole137$12,689
Lurasidone Hcl20$10,954
Divalproex Sodium ErDivalproex Sodium170$8,621
Oxcarbazepine48$7,874
Venlafaxine Hcl ErVenlafaxine Hcl120$5,550
Trazodone Hcl211$4,184
Clozapine30$3,817
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine48$3,753
Duloxetine Hcl74$3,339
Lamotrigine139$2,817
Desvenlafaxine Succinate ErDesvenlafaxine Succinate33$2,723
Lorazepam174$2,584
Sertraline Hcl178$2,368
Bupropion XlBupropion Hcl84$2,323
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine89$2,116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$26$2,368178 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →